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ARTICLE
Nrf2 activation does not affect adenoma
development in a mouse model of colorectal cancer
Elena V. Knatko1, Cecilia Castro2, Maureen Higgins1, Ying Zhang1, Tadashi Honda 3, Colin J. Henderson4,
C. Roland Wolf4, Julian L. Griffin 2,5 & Albena T. Dinkova-Kostova 1,6✉
Transcription factor nuclear factor erythroid 2 p45-related factor 2 (Nrf2) and its main
negative regulator, Kelch-like ECH associated protein 1 (Keap1), are at the interface between
redox and intermediary metabolism. Nrf2 activation is protective in models of human disease
and has benefits in clinical trials. Consequently, the Keap1/Nrf2 protein complex is a drug
target. However, in cancer Nrf2 plays a dual role, raising concerns that Nrf2 activators may
promote growth of early neoplasms. To address this concern, we examined the role of Nrf2 in
development of colorectal adenomas by employing genetic, pharmacological, and metabo-
lomic approaches. We found that colorectal adenomas that form in Gstp−/−: ApcMin/+ mice
are characterized by altered one-carbon metabolism and that genetic activation, but not
disruption of Nrf2, enhances these metabolic alterations. However, this enhancement is
modest compared to the magnitude of metabolic differences between tumor and peri-
tumoral tissues, suggesting that the metabolic changes conferred by Nrf2 activation may
have little contribution to the early stages of carcinogenesis. Indeed, neither genetic (by
Keap1 knockdown) nor pharmacological Nrf2 activation, nor its disruption, affected colorectal
adenoma formation in this model. We conclude that pharmacological Nrf2 activation is
unlikely to impact the early stages of development of colorectal cancer.
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T o adapt to conditions of oxidative, electrophilic, andinflammatory stress, cells have evolved networks of cyto-protective proteins, the gene expression of which is con-
trolled by transcription factor nuclear factor erythroid 2 p45-
related factor 2 (Nrf2) and its main negative regulator the Kelch-
like ECH associated protein 1 (Keap1)1. Activation of Nrf2 has
shown protective effects in numerous animal models of chronic
disease2 and has beneficial effects in human clinical trials3. Nrf2 is
considered a drug target, and several small molecule Nrf2 indu-
cers are currently at various stages of drug development4. Among
them, the naturally occurring isothiocyanate sulforaphane, the
semi-synthetic pentacyclic cyanoenone triterpenoids, and their
tricyclic derivatives are the most potent Nrf2 inducers known to
date5–8. The cyanoenones activate Nrf2 at low nanomolar con-
centrations by modifying C151 in Keap19,10. The tricyclic cya-
noenone TBE-31 is highly bioavailable11, has a covalent and
reversible mode of action, and is suitable for chronic oral
administration12. Furthermore, TBE-31 has demonstrated pro-
tective effects in mouse models of cutaneous squamous cell
carcinoma13, and non-alcoholic steatohepatitis14 and in a rat
model of aflatoxin-induced hepatocarcinogenesis6.
Although Nrf2 is primarily regulated at the protein stability
level, the expression of NFE2L2, the gene encoding Nrf2, is
another important determinant of cellular Nrf2 levels, which
has been shown to affect susceptibility to disease. Thus, a single
nucleotide polymorphism (SNP) in the human NFE2L2 pro-
moter lowers its gene expression and increases the risk for lung
cancer15. However, persistent activation of Nrf2 is frequently
exploited by cancer cells, where it promotes their survival and
resistance to chemotherapy and radiation therapy16,17, and
contributes to metabolic adaptation18. Mutations in Keap1 or
Nrf2, which abrogate formation of the Keap1/Nrf2 protein
complex or prevent Nrf2 ubiquitination, leading to its con-
stitutive activation, occur in several types of human cancer, and
are particularly prominent in squamous cell carcinomas of the
lung, contributing to tumor growth and resistance to chemo-
and radiation therapy19,20. Importantly, it was recently shown
in the context of non-small cell lung cancer that constitutively
active Nrf2 generates enhancers at gene loci that are not nor-
mally regulated following transient activation of Nrf2 under
physiological conditions21. Nrf2 is also upregulated in human
colorectal tumors, where high levels of nuclear Nrf2 correlate
with poor patient prognosis22. However, whether Nrf2 affects
the early stages of adenoma development in the colon is
unclear.
It is well established that in human colorectal cancers, the
adenomatous polyposis coli (APC) gene is frequently
mutated23 or inactivated by promoter hypermethylation24,
and its germline mutations cause familial adenomatous poly-
posis (FAP), an autosomal dominant inherited condition in
which numerous adenomas form in the epithelium of the large
intestine25. Similar to humans, ApcMin/+mice that have a
mutant allele encoding a nonsense mutation at codon 850 of
the murine Apc gene, are predisposed to intestinal adenoma
formation, but unlike in humans, the tumors in mice form
predominantly in the small intestine26. Interestingly, ApcMin/
+mice that are also deficient for glutathione transferase Pi
(Gstp−/−: ApcMin/+) have a 6-fold increase in colon adenoma
incidence, and a 50-fold increase in colorectal adenoma
multiplicity, in comparison with their Gstp wild-type (Gstp
+/+: ApcMin/+) counterparts27. Using the Gstp−/−: ApcMin/+
mouse model, in this study we examined the role of Nrf2 in
the development of colorectal adenomas by employing genetic
and pharmacological approaches. We then used metabolomics
to characterize tumorous and non-tumorous tissue from mice
with different levels of Nrf2.
Results
The expression of classical Nrf2 targets and pro-inflammatory
genes is not affected by deletion of Gstp. Because Gstp is
involved in xenobiotic metabolism28 as well as cell signaling, by
sequestering c-Jun N-terminal kinase (JNK)29, we first asked
whether deletion of Gstp affects the Nrf2-mediated transcription
using the classical Nrf2-target NAD(P)H:quinone oxidoreductase
1 (Nqo1) as a marker, which is expressed in an Nrf2-dependent
manner in the mouse colon30. The mRNA levels for Nqo1 in the
colon tissues did not differ between Gstp+/+ and Gstp−/− animals
(Fig. 1a). As expected, these levels were ~60% lower in mice with
disrupted Nrf2 (Gstp−/−: Nrf2−/−) and ~4-fold higher in mice
with high Nrf2 levels due to Keap1 downregulation (Gstp−/−:
Keap1flox/flox) (Fig. 1a).
The GSTs are a large family of detoxification enzymes, and we
next asked whether deletion of Gstp affected the expression of
other members of the GST family. The mRNA levels in the colon
for Gsta1/2 (Fig. 1b), Gsta3 (Fig. 1c), and Gstm (Fig. 1d) did not
differ significantly between Gstp−/−: Nrf2+/+: Keap1+/+ and
Gstp+/+: Nrf2+/+: Keap1+/+ mice. As expected based on
published work comparing their expression in the intestine of
wild-type and Nrf2-knockout mice31, the expression levels of
Gsta3 and Gstm were lower in Nrf2−/− and higher in Keap1flox/
flox mice, in comparison with their Nrf2+/+ and Keap1+/+
counterparts (Fig. 1c, d). By contrast, the mRNA levels for the
pro-inflammatory cytokines interleukin-6 (Il6) (Fig. 1e) and Il1β
(Fig. 1f) were lower in Keap1flox/flox mice. The basal levels of
expression of prostaglandin-endoperoxide synthase 2 (Ptgs2),
more commonly known as cyclooxygenase 2 (Cox2), were not
affected by Gstp deletion, Nrf2 disruption or Keap1 knockdown
(Fig. 1g).
Genetic activation or disruption of Nrf2 does not affect colorectal
adenoma formation in Gstp−/−: ApcMin/+ mice. To address whe-
ther genetic activation or disruption of Nrf2 affects the development
of colorectal tumors, we generated Gstp−/−: ApcMin/+: Nrf2−/−:
Keap1+/+ and Gstp−/−: ApcMin/+: Nrf2+/+: Keap1flox/flox mice by
crossing Gstp−/−: ApcMin/+ mice with Nrf2−/− or Keap1flox/flox
mice, respectively, all on the C57BL/6 genetic background. For sim-
plicity, throughout the rest of the manuscript, we refer to these
genotypes of mice as follows: Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+
= wild-type (WT); Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+ = Nrf2-
knockout (Nrf2-KO); and Gstp−/−: ApcMin/+: Nrf2+/+: Keap1flox/flox
mice=Keap1-knockdown (Keap1-KD). The number and volume of
colon neoplasms (>1mm height) were assessed at 20 weeks (when
due to welfare concerns, many animals had to be euthanized) in order
to establish whether genetic activation or disruption of Nrf2 affects
the development of colorectal adenoma. We found that the multi-
plicity of tumors was not affected by either disruption of Nrf2 or its
genetic upregulation by Keap1 knockdown (Fig. 2a, b). Interestingly,
the multiplicity of large (>2.5mm diameter) tumors tended to be
lower in female mice than in male mice, again with no significant
differences among the genotypes (Fig. 2c, d). Overall tumor burden
was also similar among the genotypes, and greater in male than
female animals (Fig. 2e, f).
Nrf2 activation does not affect the expression of pro-
inflammatory cytokines in tumor or peri-tumoral tissue. In a
subset of mice, we determined the expression of the pro-
inflammatory cytokines Il6 and Il1β, and the pro-inflammatory
enzyme Ptgs2. The mRNA levels for both cytokines were higher
in tumor compared to peri-tumoral tissue, had high inter-tumor
variability, and did not differ significantly among the genotypes
(Fig. 3a, b). The expression of Ptgs2 was increased in the tumors
(Fig. 3c), although this increase was smaller in tumors from
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Keap1-KD mice in comparison with WT or Nrf2-KO, consistent
with our previous observations of a reciprocal relation between
pharmacological Nrf2 activation and interferon-γ (IFNγ)-stimu-
lated Ptgs2 transcription5. The expression of the anti-
inflammatory cytokine Il10 in tumor tissue was not affected by
either Nrf2 disruption or genetic activation (Fig. 3d). Notably, the
mRNA levels for Nqo1 in tumor and peri-tumoral tissues in WT
(i.e. Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+) mice were highly
variable among 12 randomly selected individual animals (Fig. 3e),
suggesting no consistent changes in Nrf2-transcriptional activity
during adenoma development. Although lower than in WT, as
expected based on its regulation by Nrf2, the Nqo1 expression did
not differ between tumor and peri-tumoral tissues of Nrf2-KO
mice. Similarly, the mRNA levels for Gclc and Gclm, two other
Nrf2-transcriptional targets encoding the catalytic and the
modifier subunits, respectively, of glutamate-cysteine ligase, the
Fig. 1 The expression of classical Nrf2 targets and pro-inflammatory genes is not affected by deletion of Gstp. mRNA levels for Nqo1 (a), Gsta1/2 (b),
Gsta3 (c), Gstm (d), Il6 (e) Il1β (f), and Ptgs2 (g) in colon tissue of Gstp+/+: Nrf2+/+: Keap1+/+ (green circles), Gstp−/−: Nrf2+/+: Keap1+/+ (black
circles), Gstp−/−: Nrf2−/−: Keap1+/+ (blue circles), and Gstp−/−: Nrf2+/+: Keap1flox/flox (red circles) female mice (n= 8). Results are expressed as
relative values to the Gstp+/+: Nrf2+/+: Keap1+/+ genotype. Actb was used as the reference gene. *p < 0.01 (compared to Gstp+/+: Nrf2+/+: Keap1+/+).
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enzyme catalyzing the rate-limiting step in the biosynthesis of
glutathione (GSH), were similar in tumor compared to peri-
tumoral tissue, although both were higher in tissues from Keap1-
KD compared to WT mice (Fig. 3f, g), as expected31. Interest-
ingly, however, the mRNA (Fig. 3h) and the protein (Fig. 3i)
levels for heme oxygenase 1 (Hmox1), which is also partly
regulated by Nrf2, were profoundly increased in tumor vs. peri-
tumoral tissues. The protein levels of Hmox1 were lowest in Nrf2-
KO and highest in Keap1-KD peri-tumoral tissues, as expected.
By contrast, the increase in Hmox1 levels in the tumor tissues was
higher in Nrf2-KO than in WT mice, indicating that transcription
factors other than Nrf2 were responsible for it. Considering that
the expression of Hmox1 is also regulated by the pro-
inflammatory transcription factor nuclear factor κB (NFκB) and
activator protein 1 (AP1)32, and that Hmox1 is known to be
upregulated in inflamed colonic tissues33, we speculate that the
enhanced Hmox1 expression in the tumors is at least in part due
to the markedly enhanced inflammation in tumor compared to
peri-tumoral tissue (Fig. 3a–c).
Colorectal adenomas that form in Gstp−/−: ApcMin/+ mice are
characterized by altered one-carbon metabolism. By use of
metabolomics, combining nuclear magnetic resonance (NMR)
spectroscopy and two complementary liquid chromatography
mass spectrometry (LC-MS) approaches, we examined if we could
identify a metabolic signature induced by the tumor, irrespec-
tively of the genotype. Multivariate analysis of both the NMR
spectroscopy (Fig. 4a, b) and the LC-MS data (Fig. 5a–d) showed
a clear separation between tumors and peri-tumoral tissues,
indicating distinct metabolic states, with no apparent subgroup-
ing related to the genotype. The NMR spectroscopy analysis
showed significantly higher levels of betaine, AMP, succinate,
alanine, glutamate, glutamine, glycine, aspartate, and malate
(Fig. 6a–c and Supplementary Fig. 1) in the tumors compared to
peri-tumoral tissues, and lower levels of myo-inositol, creatine
and inosine (Fig. 6d, e). The increase in betaine (Fig. 6a) was
particularly intriguing, due to its role in methylation. The LC-MS
analyses confirmed the higher AMP levels in tumors, and further
showed increases in the ribonucleotides GMP, CMP and UMP
(Supplementary Fig. 1c and Supplementary Fig. 2). This analysis
also confirmed the increased glutamate and glycine levels, and
additionally showed that the levels of proline, hydoxyproline and
CDP-choline were also increased (Supplementary Fig. 1d, e).
Furthermore, in addition to confirming higher levels of betaine
(Supplementary Fig. 1f), this analysis revealed increases in cho-
line, S-adenosyl methionine (SAM), S-adenosyl homocysteine
(SAH) (Supplementary Fig. 1f, g), and cystathionine (Supple-
mentary Fig. 1e). Together, these changes indicate that one-
carbon metabolism is altered in the colorectal adenomas from
Gstp−/−: ApcMin/+ mice.
Knockdown of Keap1, but not disruption of Nrf2, enhances the
metabolic alterations in colorectal adenomas from Gstp−/−:
ApcMin/+ mice. We next focused our analysis on differences
among the genotypes within the same type of tissue. Both the
NMR spectroscopy and the LC-MS analyses showed that the
levels of glutathione were higher in both tumors and peri-tumoral
tissues from Keap1-KD mice, in comparison with their WT and
Nrf2-KO counterparts (Fig. 6g, h), in close agreement with the
higher expression levels of Gclc and Gclm (Fig. 3f, g). Glutathione
levels tend towards an increase, but this increase is not statisti-
cally significant between peri-tumor and tumor samples
(p= 0.059), if the genotype factor is ignored. However, plotting
its levels in all three genotypes in both types of tissue shows the
different behavior in each case. Significantly different amounts of
glutathione were found in both the peri-tumoral tissues (ANOVA
p= 1.37E−8) and the tumors (ANOVA p= 5.42E−7), with a
particular increase in the Keap1-KD genotype in both cases. This
plot also shows that Nrf2-KO is the only genotype where glu-
tathione increases in the tumors.
In general, the differences in metabolites between WT and
Keap1-KD were greater than the differences between WT and
Nrf2-KO genotypes in both tumor and peri-tumoral tissues.
Thus, compared to WT, the levels of myo-inositol (Fig. 6d),
betaine (Fig. 6a), AMP (Fig. 6b), succinate (Fig. 6c), creatine
(Fig. 6e) and NAD (Fig. 7b) were higher in tumor tissue of
Fig. 2 Genetic activation or disruption of Nrf2 does not affect colorectal
adenoma formation in Gstp−/−: ApcMin/+ mice. Tumor multiplicity (a–d)
and burden (e, f) in colons of 20-week-old Gstp−/−: ApcMin/+: Nrf2+/+:
Keap1+/+ (WT, black circles), Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+(Nrf2-
KO, blue circles), and Gstp−/−: ApcMin/+: Nrf2+/+: Keap1flox/flox (Keap1-KD,
red circles) mice (n= 38–40).
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Keap1-KD mice, whereas the levels of methionine (Fig. 7c) and
methionine sulfoxide (Fig. 7d) were lower. By contrast, only the
levels of AMP (Fig. 6b) and methionine (Fig. 7c) differed between
WT and Nrf2-KO tumors. In peri-tumoral tissue, the levels of
myo-inositol (Fig. 6d), succinate (Fig. 6c), creatine (Fig. 6e), NAD
(Fig. 7b), and inosine (Fig. 6f) were higher in Keap1-KD
compared to WT mice, whereas the levels of serine (Fig. 7e)
and histidine (Fig. 7f) were lower. Interestingly, the levels of
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cystathione were increased in the tumors, and although still
increased in tumor compared to peri-tumoral tissue, were lower
in tumors from Keap1-KD and higher in tumors from Nrf2-KO
mice (Fig. 7a). Finally, symmetric dimethylarginine (SDMA)
(Fig. 7g), asymmetric dimethylarginine (ADMA) (Fig. 7h) and
phenylalanine (Fig. 7i) were markedly increased in tumor
compared to peri-tumoral tissue, but these increases were much
less pronounced in tumors from either Keap1-KD or Nrf2-KO
mice.
Overall, most differences in metabolites between tumor and
peri-tumoral tissues were enhanced in Keap1-KD mice; however,
the magnitude of this enhancement was much more modest in
comparison with the magnitude of the differences between tumor
and peri-tumoral tissues. This observation is further supported by
the fact that the mRNA levels for glucose-6-phosphate dehy-
drogenase (G6pdx and G6pd2) (Fig. 8a, b) and the pentose
phosphate pathway enzyme phosphogluconate dehydrogenase
(Pgd) (Fig. 8c), which increase upon Nrf2 activation in rapidly
Fig. 3 Nrf2 activation does not affect the expression of pro-inflammatory cytokines in tumor or peri-tumoral tissue. a–c mRNA levels for Il1β (a), Il6 (b)
Ptgs2 (c), and Il10 (d) in colorectal tumors and peri-tumoral colon tissue of female Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT), Gstp−/−: ApcMin/+:
Nrf2−/−: Keap1+/+(Nrf2-KO), and Gstp−/−: ApcMin/+: Nrf2+/+: Keap1flox/flox (Keap1-KD) mice (n= 5–11). Hprt1 was used as the reference gene. e mRNA
levels for Nqo1 in tumor vs. peri-tumoral tissues in Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT) and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+ (Nrf2-KO)
mice (n= 12). Rplp0 was used as the reference gene. f–h mRNA levels for Gclc (f), Gclm (g), and Hmox1 (h) in tumor vs. peri-tumoral tissues in Gstp−/−:
ApcMin/+: Nrf2+/+: Keap1+/+ (WT) and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+(Nrf2-KO) mice (n= 5–6). Rplp0 was used as the reference gene. i Protein
levels for Hmox1 in tumor vs. peri-tumoral tissues in Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT) and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+(Nrf2-KO)
mice (n= 4). β-actin was used as loading control. *p < 0.05 vs. WT peri-tumor; **p < 0.05 tumor vs. peri-tumor.
Fig. 4 Tumor and peri-tumoral tissues have distinct metabolic states as revealed by NMR spectroscopy analysis. a Principal component analysis (PCA)
score plot from NMR data for total fatty acids (R2= 75.9% and Q2= 41.7%). At least seven independent biological replicates of colon tissue from peri-
tumorous (red) and tumorous (black) tissues were included. b Plot showing the individual metabolites driving the separation among the tissue types
(loadings), with the variables (i.e., metabolites) represented in green circles (Asp= aspartate and Asn= asparagine).
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proliferating cells18, were not different among the Nrf2/Keap1
genotypes. Interestingly, the expression of G6pdx was increased
in tumor in comparison with peri-tumoral tissues, whereas that of
G6pd2 was decreased, and the mRNA levels for Pgd were
unchanged. Together, these findings suggest that in this model,
the enhanced metabolic changes conferred by the Keap1
knockdown may have negligible contribution to the carcinogen-
esis process, a conclusion also supported by the fact that neither
Keap1 knockdown nor disruption of Nrf2 affected colorectal
adenoma formation in Gstp−/−: ApcMin/+ mice (Fig. 2).
Chronic pharmacological activation of Nrf2 by TBE-31 does
not affect colorectal adenoma formation in Gstp−/−: ApcMin/+
mice. We used the potent tricyclic cyanoenone TBE-31 (Fig. 9a)
to activate Nrf2 pharmacologically. The mRNA levels for Nqo1
(Fig. 9b), were increased by oral administration of TBE-31,
confirming Nrf2 activation in the colons of Gstp−/−: ApcMin/+
mice.
In full agreement with the previous experiment (Fig. 2), there
was no significant difference in tumor multiplicity (Fig. 9c, d) or
burden (Fig. 9e) between WT and Nrf2-KO mice, confirming that
the absence of functional Nrf2 neither accelerates nor inhibits
tumor development in this model. Consistent with the lack of
effect of genetic Nrf2 activation by Keap1 knockdown, chronic
intervention with TBE-31 (5 nmol/g body weight, orally, 3 days
per week for 12 weeks, starting at week 8 of age) did not affect
tumor development in Gstp+−/+−: ApcMin/+ mice.
Genetic activation or disruption of Nrf2 does not affect col-
orectal adenoma formation in Gstp−/−: ApcMin/+ mice fed
high-fat diet. The combination of high-fat diet and Apc truncation
has been shown to alter the bile acid profile, antagonizing the
function of intestinal farnesoid X receptor (FXR) to drive malignant
transformation in cancer stem cells34. Thus, we asked if genetic
alterations in Nrf2 may affect tumor development in mice fed high-
fat diet, which is increasingly more common worldwide. To this
end, starting at week 6 of age, the animals were fed diet delivering
60% of calories from fat for 9 weeks, and tumor development was
assessed at week 15. Although Keap1 is the main negative regulator
of Nrf2, the activity of the transcription factor in cancer is also
affected by several other proteins35. Similarly, in addition to Nrf2,
Keap1 regulates the function of other cellular proteins36. Thus, in
addition to the three genotypes (i.e. WT, Nrf2-KO and Keap1-KD),
for this experiment we also generated a fourth category of mice
combining Nrf2 deficiency and Keap1 downregulation, namely
Gstp−/−: ApcMin/+: Nrf2−/−: Keap1flox/flox, to which we refer as
Nrf2-KO/Keap1-KD double-transgenic mice. Consistent with the
carcinogenesis experiments described above, all mice were Gstp−/−:
ApcMin/+. Once again, we found that tumor multiplicity tended to
be higher in male than in female mice, and that there were no
significant differences in the multiplicity (Fig. 10a–d) or burden
(Fig. 10e, f) of colorectal tumors among any of the four genotypes,
in close agreement with the previous experiments in mice fed
standard diet (Figs. 2, 9c–e). This experiment further confirmed the
conclusion that disruption of Nrf2 or its constitutive upregulation
by either genetic or pharmacological means, does not affect
Fig. 5 Tumor and peri-tumoral tissues have distinct metabolic states as
revealed by LC-MS analysis. a, b Partial least square-discriminant analysis
(PLS-DA) score plot from LC-MS data for aqueous metabolites, analyzed
by: a C18pfp-based method (R2X= 71.9%, R2Y= 94% and Q2= 89.3%)
(a); and a behamide-based method (R2X= 55.8%, R2Y= 80.1% and
Q2= 74.7%) (b). In both cases, at least seven independent biological
replicates of colon tissue from peri-tumorous (red) and tumorous (black)
tissues were included. c, d Plots showing the individual metabolites driving
the separation among the tissue types (loadings), for the C18pfp-based
method (c) and the behamide-based method (d), with the variables (i.e.,
metabolites) represented in green circles, while the center for each
genotype (peri-tumorous-DA(1), tumorous-DA(2)) is in blue.
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colorectal adenoma development in this mouse model even under
conditions of high-fat diet.
Notably, it was necessary to terminate the high-fat diet
experiment earlier than the experiments on standard diet, when
the animals were 15- rather than 20-week old, and we had to
enroll many more mice as a number of them had to be sacrificed
before the 15-week endpoint. This necessity was related to
concerns for animal welfare, the close monitoring of which
Fig. 6 Colorectal adenomas have altered metabolite levels in comparison with matched peri-tumorous tissue. a–f Concentration of selected metabolites
in peri-tumorous and tumorous tissues of wild-type (white bars), Keap1-KD (gray bars) and Nrf2-KO (black bars) mice as measured by NMR. (a) betaine,
(b) AMP, (c) succinate, (d) myo-inositol, (e) creatine, (f) inosine. g, h Concentration of glutathione (GSH) (g) and GSSG (h) in peri-tumorous and tumorous
tissues of wild-type (white bars), Keap1-KD (black bars) and Nrf2-KO (gray bars) as measured by NMR. *0.05 > p > 0.01, ** 0.01 > p > 0.001, ***p < 0.001,
using ANOVA followed by Tukey post-hoc test for statistical significance.
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showed that many of the mice on high-fat diet developed anemia
earlier than those on standard diet. Indeed, it has been shown that
C57BL/6 mice fed high-fat diet for 8 weeks develop iron
deficiency due to diminished intestinal iron uptake37. Curiously,
we found that anemia was more prevalent in Keap1-KD animals
than in any of the other three genotypes (p < 0.001 for Keap1-KD
vs. WT; p= 0.012 for Keap1-KD vs. Nrf2-KO; p= 0.005 for
Keap1-KD vs. Nrf2-KO/Keap1-KD). Thus, the percentage of
anemic mice within each genotype was: WT: 4.8% (3/62; 3 males
and 0 females), Nrf2-KO: 11.7% (7/60; 5 males and 2 females),
Keap1-KD: 27.4% (17/62; 9 males and 8 females), and Nrf2-KO/
Keap1-KD: 9.8% (6/61; 4 males and 2 females). We hypothesized
that the increased anemia in the Keap1-KD mice was at least in
part caused by the documented Nrf2-dependent transcription of
bone morphogenetic protein 6 (Bmp6) in liver sinusoidal
endothelial cells38. This is because Bmp6 is known to regulate
the synthesis of the liver hormone hepcidin, reducing serum iron
levels39. Therefore, we measured the hepatic mRNA levels for
Bmp6, and found them to be higher in livers of Keap1-KD mice
compared to their WT or Nrf2-KO counterparts (Fig. 10g).
Consistent with Nrf2 dependence, the hepatic expression levels of
Bmp6 did not differ from WT in Keap1-KD mice with disrupted
Nrf2 (i.e. Nrf2-KO/Keap1-KD double transgenic) mice. We
attribute the small magnitude of hepatic Bmp6 increase in Keap1-
KD mice to the fact that the liver sinusoidal endothelial cells
represent ~15% of the total liver cell population, and only 3% of
the liver volume40. Alternatively, it is possible that other
transcription factors attenuate the Nrf2-mediated increase in
Bmp6 transcription, such as HIF1α, which is upregulated by iron
deficiency41, and has been shown to downregulate the expression
Fig. 7 Knockdown of Keap1 enhances the metabolic alterations in colorectal adenomas. Concentration of selected metabolites in peri-tumorous and
tumorous tissues of wild-type (white bars), Keap1-KD (gray bars) and Nrf2-KO (black bars) mice as measured by LC-MS using the C18pfp-based method.
(a) cystathione, (b) NAD, (c) methionine, (d) methionine sulfoxide (MetSO), (e) serine, (f) histidine, (g) symmetric dimethylarginine (SDMA), (h)
asymmetric dimethylarginine (ADMA), (i) phenylalanine. *0.05 > p > 0.01, **0.01 > p > 0.001, ***p < 0.001, using ANOVA followed by Tukey post-hoc test
for statistical significance.
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of Bmp642 as well as to counteract Nrf2-dependent gene
expression43.
Discussion
Over the years since its discovery, Nrf2 has been attributed both
tumor-suppressing and tumor-promoting effects, and has been
linked to the hallmarks of cancer44. Activation of Nrf2 is com-
monly observed in established human tumors45, raising concerns
over the current drug development and clinical use of pharma-
cological Nrf2 activators. In this study, we addressed this concern
by use of a mouse model of colorectal cancer initiated by a
truncation of the Apc gene. Inactivating mutations of both alleles
of the tumor suppressor APC represent one of the earliest events
in the colorectal carcinogenesis in humans46. Our results show
that neither genetic (by Keap1 knockdown) nor pharmacological
(by a potent activator, the cyanoenone TBE-31) Nrf2 activation
affects adenoma development at the early stages. However, Nrf2
is upregulated in human colorectal tumors and correlates with
poor patient prognosis22, and thus it is probable that Nrf2 acti-
vation occurs later in the carcinogenesis process, such as during
transition from adenoma to adenocarcinoma, supporting tumor
growth. Further studies are needed to examine this possibility,
which would require the use of a different animal model. One
restriction of the model used in our study is that, in keeping with
animal welfare regulations, it is not possible to maintain the
experimental mice beyond the adenoma stage of the tumors,
which limits its clinical relevance to the early stages of the car-
cinogenesis process.
TBE-31 is a cyanoenone, which shares the same electrophilic
centers with bardoxolone methyl (CDDO-Me) and RTA-408, two
pentacyclic cyanoenone triterpenoids, which are currently in
advanced clinical trials for a number of disease indications,
including Alport syndrome, chronic kidney disease associated
with type 2 diabetes mellitus, liver disease, Friedreich’s ataxia4,47,
and in patients hospitalized with confirmed COVID-19
(NCT04494646). The concern that pharmacological Nrf2 activa-
tion may promote the development of early neoplastic lesions is
particularly relevant to colorectal cancer, because it is the third
most common cancer globally in both men and women, with high
mortality rates48, and because orally-administered pharmacolo-
gical Nrf2 activators are in direct contact with the gastrointestinal
tract epithelium. The findings from our study suggest that it is
unlikely that pharmacological Nrf2 activators that are being
developed for clinical use will promote the initiation of colorectal
cancer.
Using LC-MS analysis of metabolites in colon tissue extracts,
we recently found that the levels of glucose 6-phosphate and
fructose 6-phosphate, metabolites involved in the initial steps of
glycolysis, were higher in colons of Keap1-KD mice in compar-
ison with their WT counterparts, whereas dihydroxyacetone
phosphate and glyceraldehyde 3-phosphate, which are involved in
the later steps of glycolysis, were lower30. Additionally, gas
chromatography-MS (GC-MS) analysis showed that the levels of
saturated and mono-unsaturated fatty acids were lower in Keap1-
KD mice, whereas the levels of polyunsaturated fatty acids were
higher. Together, these findings indicate that knockdown of
Keap1, and the consequent activation of Nrf2, affect multiple
aspects of intermediary metabolism in the healthy colon. Here, we
show that the differences in metabolites between tumor and peri-
tumoral colon tissues of Gstp−/−: ApcMin/+ mice are enhanced
by Keap1 knockdown. Nonetheless, the magnitude of this
enhancement is modest compared to the magnitude of the dif-
ference in the metabolic state between tumor and peri-tumoral
tissues. These observations, together with the finding that neither
genetic Keap1 knockdown nor its pharmacological inactivation
by TBE-31 affects adenoma formation, lead us to conclude that in
this model, the enhanced metabolic changes conferred by the
Keap1 knockdown do not substantially contribute to the early
stages of the colorectal carcinogenesis process.
It is noteworthy that tumor multiplicity, particularly that of
large (>2.5 mm diameter) tumors, and burden are consistently
higher in male than in female mice in all of our experiments. This
finding is in agreement with the increased prevalence of colorectal
cancer in males in human populations49 and the enhanced ade-
noma multiplicity in the colon of ApcMin/+ mice (that are wild-
type for Gstp) and rats carrying a nonsense mutation in the Apc
gene, termed Polyposis in the rat colon (ApcPirc/+), as well as in
rat models of colorectal carcinogenesis induced by the chemical
carcinogens 1,2-dimethylhydrazine50 or azoxymethane51.
Detailed studies by Amos-Landgraf et al51. have found that nei-
ther ovariectomy nor hormone replacement affected the pre-
valence of adenomas in female ApcPirc/+ rats, whereas
orchidectomy reduced adenoma development in their male
counterparts, and supplementation with testosterone reversed this
effect. Thus, as in the above discussed colorectal cancer models,
the observed sexual dimorphism in multiplicity of colonic tumors
Fig. 8 The expression of G6pdx, G6pd2 and Pgd is not coordinately altered in colorectal adenomas. a–c mRNA levels for G6pd2 (a), G6pdx (b) and Pgd
(c) in tumor vs. peri-tumoral tissues in Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT) and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+(Nrf2-KO) mice
(n= 5–6). Rplp0 was used as the reference gene. *p < 0.05 vs. WT peri-tumor; **p < 0.05 tumor vs. peri-tumor.
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Fig. 9 Chronic pharmacological activation of Nrf2 by TBE-31 does not affect colorectal adenoma formation in Gstp−/−: ApcMin/+ mice. a Chemical
structure of TBE-31. b mRNA levels for Nqo1 in colons from Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT) mice (n= 3–4) that had been treated with
vehicle (0.7% DMSO in corn oil) or the indicated doses of TBE-31, per os, 3 days per week for 1 week, 72h-, 48h- and 48h-apart; colon tissue was harvested
24 h after the last dose. Actb was used as the reference gene. *p < 0.05 vs. vehicle-treated. c–e Tumor multiplicity (c, d) and burden (e) in colons of 20-
week-old Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT, black circles) and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+(Nrf2-KO, blue circles) mice
(n= 27–30) that had been treated per os with vehicle (0.7% v/v DMSO in corn oil, closed circles) or TBE-31 (5 nmol/g body weight, 3 days per week for
12 weeks, starting at week 8 of age, open circles).
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in our model is more likely due to tumor promotion by male
hormones rather than protection by female hormones51.
Cheung et al.27 have reported increased inflammation and
intestinal carcinogenesis in Gstp+/+: ApcMin/+: Nrf2−/−:
Keap1+/+ mice52. In our model, unbiased pathway enrichment
analysis following mRNA profiling, as well as additional
supportive biochemical analyses, revealed that the absence of
Gstp promotes a state of enhanced inflammation, accompanied
by a 6-fold increase in colon adenoma incidence, and a 50-fold
increase in colorectal adenoma multiplicity. The present study
confirmed the profound increase in pro-inflammatory markers
(Il6, Il1β, and Ptgs2) in tumor compared to peri-tumoral tissue in
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mice of all genotypes (Fig. 3a–c). Importantly however, Nrf2
disruption did not increase inflammation further (Fig. 3a–c).
Together, these studies illustrate the critical importance of
inflammation in colorectal adenoma formation, consistent with
the tumor-suppressive effects of anti-inflammatory drugs, such as
celecoxib53,54 and aspirin55,56 in ApcMin/+ mice, and the epide-
miological data showing association of regular aspirin use with
reduced incidence of colorectal cancer in humans57.
Of note, quantitative proteomic analysis of livers from Gstp−/−
mice, which were used to obtain the Gstp−/−: ApcMin/+ mice,
showed similar overall protein S-glutathionylation profiles to
those of their Gstp+/+ counterparts, indicating that whereas Gstp
may be involved in catalyzing S-glutathionylation of some pro-
teins in response to oxidative stress, including Keap158, its role in
global S-glutathionylation is limited59. Nonetheless, the absence
of Gstp is an important aspect of our mouse models because S-
glutathionylation of Keap1 may lead to Nrf2 activation58.
An interesting corollary of this study is the observation that a
number of metabolites involved in one-carbon metabolism
(comprising the folate and methionine cycles) are altered in the
colorectal adenomas from Gstp−/−: ApcMin/+ mice. The
enhanced effect of the Keap1 knockdown is consistent with the
importance of Keap1/Nrf2 for mitochondrial health60,61, which in
turn supports one-carbon metabolism62. One-carbon metabolism
and SAM have critical roles in multiple cellular processes,
including generation of precursors to nucleotide biosynthesis and
one-carbon units for DNA- and histone-methylation reactions,
and can drive tumorigenesis63. Crucially, because all tumors in
this model are adenomas27, our findings strongly suggest that
alterations in one-carbon metabolism occur early in the colorectal
carcinogenesis process, and together with changes in expression/
activity of the enzymes that catalyze their formation, these
metabolic alterations allow for the well-documented aberrations
in DNA and histone methylation in colorectal tumors from mice
and humans48. Curiously, Khor et al.64 have reported promoter
hypermethylation of NFE2L2, the gene encoding Nrf2, and a
trend for a decrease in the intensity and percentage of Nrf2-
positive cells in advanced-stage prostate cancer compared to
normal prostate tissue. Conversely, Hanada et al.65 have shown
hypermethylation of the Keap1 promoter, leading to decreased
expression and increased nuclear Nrf2 and downstream Nrf2-
target gene expression in colorectal cancer. Thus, it is possible
that the observed increase in one-carbon metabolism in our
mouse models may additionally affect Keap1 and/or Nrf2
expression via epigenetic mechanisms.
Another interesting observation from this study is the
increased prevalence of anemia in Keap1-KD animals fed high-fat
diet than in any of the other three genotypes. The fact that this
phenotype is more common in Keap1-KD than in Nrf2-KO/
Keap1-KD double-transgenic mice suggests that it is related to
Nrf2 activation rather than any other process that might be
influenced by the downregulation of Keap1. We found that the
mRNA levels for Bmp6, which controls the synthesis of the liver
hormone hepcidin that in turn lowers serum iron levels39, are
higher in livers of Keap1-KD, but importantly not in Nrf2-KO/
Keap1-KD mice, in comparison with their WT or Nrf2-KO
counterparts (Fig. 10g), consistent with Nrf2-dependent upregu-
lation of hepcidin in mice fed high-fat plus iron66 or polyphenol-
rich67 diets. In the small intestine, hepcidin is the predominant
negative regulator of iron absorption by enterocytes68. As men-
tioned in Results, additionally and independently of the levels of
hepcidin, high-fat diet feeding causes iron deficiency due to
diminished intestinal iron uptake37. Thus, the increased hepcidin
levels may exacerbate the diminished intestinal iron uptake due to
the high-fat diet by limiting dietary iron absorption by enter-
ocytes, ultimately causing anemia.
Methods
Animals. All mouse experiments were performed in accordance with the regula-
tions described in the UK Animals (Scientific Procedures) Act 1986 following
approval by the Welfare and Ethical use of Animals Committee of the University of
Dundee. Experimental design was undertaken in line the 3Rs principles of repla-
cement, reduction, and refinement (www.nc3rs.org.uk). Mice were bred and
maintained at the Medical School Resource Unit of the University of Dundee, with
free access to water and food (pelleted RM1 diet from SDS Ltd., Witham, Essex,
UK), on a 12-h light/ 12-h dark cycle, 35% humidity. Gstp−/−: ApcMin/+: Nrf2−/−:
Keap1+/+ and Gstp−/−: ApcMin/+: Nrf2+/+: Keap1flox/flox mice were generated by
crossing Gstp−/−: ApcMin/+ mice with Nrf2−/− or Keap1flox/flox mice, respectively,
all on the C57BL/6 genetic background. Both male and female mice were used in
the carcinogenesis experiments.
For administration to animals, (±)-TBE-31, synthesized as described7,69, was
dissolved in DMSO (vehicle) and diluted (1:140) in corn oil to achieve the
appropriate final concentrations indicated in the text and figures. The high-fat diet
was RM AFE 60% FAT, 20% CP, 20% CHO (M) (SDS Ltd., Code 824054).
Colorectal carcinogenesis. A scoring system was developed to monitor animal
welfare and signs of intestinal neoplasia, including occult blood in faeces, rectal
bleeding, stool consistency, anemia (by pale feet), rectal prolapse and weight loss.
Mice were euthanized at defined time-points indicated in the text and figures, or
when the scoring reached a set value. The large intestine was removed, flushed with
PBS, placed on ice, cut longitudinally, the tumors counted, and their height, length,
and width measured. Tumor volume was calculated according to a formula for the
volume of a sphere, using the average of the three dimensions as the diameter. The
tumors and peri-tumor tissue were then excised, snap-frozen in liquid N2 and
stored at −80 °C till further analysis.
Real-time quantitative PCR. Total RNA was extracted from mouse colon and
tumor tissue using RNeasy Kit (Qiagen Ltd.), and 500 ng of total RNA was reverse-
transcribed into cDNA using Omniscript RT Kit (Qiagen Ltd.). Real-time PCR was
carried out on Applied Biosystems QuantStudio™ 5 Real-Time PCR System. The
TaqMan data for the mRNA species were normalized using mouse ribosomal protein
lateral stalk subunit P0 (Rplp0), hypoxanthine phosphoribosyltransferase 1 (Hprt1)
and actin-beta (Actb) as internal controls. The TaqManTM Gene Expression Assay IDs
(Thermo) used were: Mm00607939_s1 (Actb); Mm01332882_m1 (Bmp6); Mm0051
6005_m1 (Hmox1); Mm03024075_m1 (Hprt1); Mm00658204_s1 (G6pd2); Mm042
60097_m1 (G6pdx); Mm00802655_m1 (Gclc); Mm00514996_m1 (Gclm); Mm0420
7463_m1 (GstA1/2); Mm00494798_m1 (GstA3); Mm00833915_g1 (GstM1); Mm0043
4228_m1 (Il1b); Mm00446190_m1 (Il6); Mm00439614_m1 (Il10); Mm01253561_m1
(Nqo1); Mm00503037_m1 (Pgd); Mm00478374_m1 (Ptgs2); Mm00725448_s1
(Rplp0).
Immunoblotting. Frozen tissues (15-40 µg) were disrupted by coarse grinding in
liquid N2, followed by homogenization for 40 sec in 10 volumes (µl per mg tissue)
ice-cold RIPA buffer (50 mM Tris-HCl, pH 8.0; 150 mM sodium chloride; 1.0%
NP-40; 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulfate) supplemented
with 1.4 × complete EDTA-free protease inhibitors cocktail (Roche). Homogenates
were clarified by centrifugation for 10 min at 17,000 × g at 4 °C, protein con-
centrations in the supernatants were determined by the bicinchoninic acid (BCA)
assay (Thermo) and adjusted to the same protein concentration in all samples
using RIPA buffer. Samples were then mixed with NuPAGE LDS sample buffer
(Thermo) and NuPAGE sample reducing agent (Thermo), heated for 10 min at
Fig. 10 Genetic activation or disruption of Nrf2 does not affect colorectal adenoma formation in Gstp−/−: ApcMin/+ mice fed high-fat diet. Tumor
multiplicity (a–d) and burden (e, f) in colons of 15-week-old Gstp−/−: ApcMin/+: Nrf2+/+: Keap1+/+ (WT, black circles), Gstp−/−: ApcMin/+: Nrf2−/−:
Keap1+/+(Nrf2-KO, blue circles), Gstp−/−: ApcMin/+: Nrf2+/+: Keap1flox/flox (Keap1-KD, red circles), and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1flox/flox
(Nrf2-KO/Keap1-KD, cyan circles) mice (n= 53–62) that had been fed high-fat diet for 9 weeks. g mRNA levels for Bmp6 in livers of 15-week-old Gstp−/−:
ApcMin/+: Nrf2+/+: Keap1+/+ (WT, black circles), Gstp−/−: ApcMin/+: Nrf2−/−: Keap1+/+(Nrf2-KO, blue circles), Gstp−/−: ApcMin/+: Nrf2+/+:
Keap1flox/flox (Keap1-KD, red circles), and Gstp−/−: ApcMin/+: Nrf2−/−: Keap1flox/flox (Nrf2-KO/Keap1-KD, cyan circles) mice (n= 8) that had been fed
high-fat diet for 9 weeks. Rplp0 was used as the reference gene. *p < 0.05 vs. WT.
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70 °C, and loaded at 20 µg/lane onto pre-cast gradient (4–12%) Tris-Glycine gels
(Thermo). Proteins were resolved by electrophoresis and transferred onto 0.45-µm
nitrocellulose membranes (Amersham Biosciences) at 100 V for 45 min at 4 °C.
Membranes were blocked in 5% milk in PBST (0.1% Tween-20) for 45 min, on a
rocker (60-70 rpm), at room temperature, and then incubated with the primary
antibodies at 4 °C on a rocker overnight. Dilutions of all primary and secondary
antibodies were in 5% milk in PBST (0.1% Tween-20). The following antibodies
were used: rabbit polyclonal anti-Hmox1, 1:2,000, Abcam; mouse monoclonal anti-
β-actin, 1:5,000. The uncropped/unedited scans of the immunoblots are shown in
Supplementary Fig. 3.
Metabolomics. Metabolites were extracted using the methanol/chloroform/water
(2:2:1; v/v) method70,71. Briefly, 50 mg of wet weight tissue were mixed with 600 µl
of CH3OH/CHCl3 (2:1; v/v), and the samples were homogenized with a Tissuelyser
(Qiagen, UK) for 5 min at a frequency of 20/s and sonicated for 15 min. Water and
chloroform (200 μl of each) were added to the samples before centrifugation at
13,300 rpm for 20 min. The resulting aqueous and organic phases were separated
from the protein pellets. The extraction procedure was repeated on the remaining
protein pellets as part of a double extraction procedure. Both organic and aqueous
phases were collected and evaporated to dryness. The dried samples were stored at
−80 °C until further analysis.
NMR analysis of aqueous extracts. The dried aqueous fractions were rehydrated
in 600 μl D2O, containing 0.05 mM sodium-3-(tri-methylsilyl)−2,2,3,3-tetra-
deuteriopropionate (TSP) (Cambridge Isotope Laboratories, MA, USA) as an
internal standard. The samples were analyzed using an AVANCE II+NMR
spectrometer operating at 500.13 MHz for the 1H frequency and 125.721 MHz for
the 13C frequency (Bruker, Germany) using a 5 mm TXI probe. The instrument
was equipped with TopSpin 3.2. Spectra were collected using a solvent suppression
pulse sequence based on a one-dimensional nuclear Overhauser effect spectroscopy
(NOESY) pulse sequence to saturate the residual 1H water signal (relaxation delay
= 2 s, t1 increment = 3 µs, mixing time = 150 ms, solvent presaturation applied
during the relaxation time and the mixing time). One hundred and twenty-eight
transients were collected into 16 K data points over a spectral width of 12 ppm at
27 °C. Assignment of the peaks was done with reference to published literature and
databases and the Chenomx spectral database contained in Chenomx NMR Suite
7.7 (Chenomx, Alberta, Canada).
LC-MS analysis of aqueous metabolites. Half of the extracted aqueous samples
were reconstituted in 0.1 ml 7:3 acetonitrile: 0.1 M aqueous ammonium car-
bonate containing a mixture of 8 internal standards at the concentration of
10 µM (Proline, Valine D8, Leucine D10, Lysine U13, Glutamic acid C13,
Phenyl alanine D5, Succinic acid D3, Serotonin D4) (all from Sigma Aldrich
except the glutamic acid from Cambridge Isotope Laboratories, MA, USA). The
samples were vortexed then sonicated for 15 min followed by centrifugation at
21,000 × g to pellet any remaining undissolved material. They were analyzed on
a Quantiva triple stage quadrupole mass spectrometer coupled to a Vanquish
Horizon Ultra High Performance Chromatography (UHPLC) unit (all analy-
tical instrument combinations supplied by Thermo Fisher Scientific), using a
bridged ethylene hybrid (BEH) amide hydrophilic interaction liquid chroma-
tography (HILIC) column72. The strong mobile phase (A) was 100 mM
ammonium carbonate, the weak mobile phase was acetonitrile (B) with 1:1
water:acetonitrile being used for the needle wash. The LC column used was the
BEH amide column (150 × 2.1 mm, 1.7 μm, Waters). The following linear
gradient was used: 20% A in acetonitrile for 1.5 min followed by an increase to
60% A over 2.5 min with a further 1 min at 60% A after which the column was
re-equilibrated for 1.9 min. After each chromatographic run the column was
washed with 30 column volumes of 6:4 water:acetonitrile followed by a further
10 column volumes of 95:5 acetonitrile:water for storage. The total run time
was 7 min, the flow rate was 0.6 mL/min and the injection volume was 5 μL. In
order to resolve pentose phosphates for the identification of ribose-1-
phosphate a shallower gradient was employed: 30% A in acetonitrile for
2.0 min followed by an increase to 50% A over 3.0 min with re-equilibration for
1.9 min.
The second half of the aqueous fraction was reconstituted in 0.1 mL of a 10 mM
ammonium acetate water solution containing the same mixture of 8 internal
standards at the concentration of 10 µM. The samples were vortexed then sonicated
for 15 min followed by centrifugation at 21,000 × g to pellet any remaining
undissolved material. They were analyzed with an ACE Excel 2 C18 PFP (100 A.
150 × 2.1 mm 5 µm) column. The electrospray voltage was set to 3500 V for the
positive ionization and to 2500 V for the negative ionization. Nitrogen at 48 mTorr
and 420 °C was used as a drying gas for solvent evaporation. The column was
conditioned at 30 °C. The mobile phase consisted of: (A) a 0.1% of formic acid
water solution and (B) a 0.1% of formic acid acetonitrile solution. The mobile
phase was pumped at a flow rate of 500 µL/min programmed as follows: initially
100% of A for 1.60 min, then subjected to a linear decrease from 100% to 70% of A
in 2.4 min and to 10% in 0.5 min then constant for 0.5 min and brought back to
initial condition after 0.1 min.
NMR and LC-MS data processing. NMR spectra were automatically processed in
TopSpin v 3.1 (Bruker, Germany). The integrals of the different metabolites were
obtained using Chenomx, normalizing to TSP and weight of the sample. LC-MS
chromatograms were analyzed using Xcalibur, version 2.0 (Thermo Fisher), inte-
grating each peak individually. while LC-MS peaks were normalized to the internal
standard and weight of the sample.
Statistics and reproducibility. For multivariate statistical analysis of metabolite
profiles, datasets were imported into SIMCA-P 15.0 (Sartorius AG, Gottingen,
Germany) for processing using PCA and PLS-DA (a regression extension of PCA
used for supervised classification). 1H NMR data were Pareto scaled, in which each
variable was centered and multiplied by 1/(Sk)1/2 where Sk is the standard
deviation of the variable. LC–MS data were scaled to unit variance by dividing each
variable by 1/(Sk). Univariate statistical analyses were performed using Excel
(Microsoft). Values are expressed as mean ± S.D. and the significance level was set
at p < 0.05. For three groups comparison, one-way ANOVA and Tukey post-hoc
test were used.*0.05 > p > 0.01; **0.01 > p > 0.001; ***p > 0.001. Sample sizes were
determined on the basis of published experiments using similar methodologies and
are stated in the figure legends. The experimental animals were randomly assigned
to treatment groups. For all experiments, the stated replicates are biological
replicates. For experimental carcinogenesis outcomes and metabolite analyses,
samples were processed in random order and analyzed blinded to genotype,
treatment and tissue type.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The metabolomics data have been deposited in MetaboLights, and are associated with the
identifier MTBLS2961. All other data are available from the corresponding author upon
reasonable request.
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